# Nature Type: Company Source: GetYourBrief — https://getyourbrief.com/entity/nature Canonical HTML page: https://getyourbrief.com/entity/nature ## Timeline - **2026-07-30**: Shanghai Jiaotong University launches investigation — The university forms a working group to comprehensively investigate the clinical trial and the associated Nature paper. - **2026-07-29**: Joint investigation report published — Science magazine and Retraction Watch release findings detailing the undisclosed death and ethical lapses, bringing the case to public attention. - **2026-07-26**: University investigation launched — Shanghai Jiao Tong University School of Medicine announces a special working group to investigate and promises 'serious action'. - **2026-07-23**: Investigative report published — Science and Retraction Watch publish a joint exposé revealing the death and lack of disclosure, triggering international scrutiny. - **2025**: Mei receives gene-editing therapy — Six-year-old girl with rare cognitive delay condition receives spinal infusion of trillions of engineered viruses in an experimental trial. - **2025**: Mei dies after therapy — Mei dies approximately one week after the infusion; the death is not reported publicly at the time. - **2025**: Fatal gene-editing trial conducted — A young girl receives an experimental gene-editing treatment for a developmental-delay-linked genetic defect at Xinhua Hospital; she later dies, an outcome the ethics board deems treatment-related. - **2018-11**: He Jiankui gene-edited babies scandal breaks — Chinese scientist He Jiankui announces the birth of the world’s first gene-edited babies, triggering global outrage and prompting China to tighten research regulations. ## Recent coverage (7 stories, network-wide) ### Hungary's 99% drought exposes 80% wetland loss; Lake Velence at 20 cm 2026-08-21 11:43:14 · Sector: climate · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Hungary's record drought is exposing the hidden cost of draining its wetlands for generations. Lake Velence has fallen to 20 centimeters, and 99% of land is under severe or extreme drought, threatening crops, drinking water, and the country's only nuclear power plant. The crisis is a case study in how historical water-management choices amplify climate-driven extremes. Full story: https://getclimatebrief.com/story/hungary-drought-wetland-loss-lake-velence ### 75% of U.S. Scientists Consider Leaving; UK Recruits 3 Elite Experts 2026-08-01 19:43:07 · Sector: hr · Sentiment: Neutral · Impact: 5/10 · Sources: 5 HR leaders face a talent crisis as prominent researchers Megan Peters, Tamara Swaab, and Ron Mangun opt for U.K. positions, reflecting a wider trend: 75% of surveyed scientists are considering leaving the U.S. The shift demands proactive workforce retention strategies. Full story: https://gethrbrief.com/story/scientist-exodus-talent-hr-uk ### 33% Spike in U.S. Scientists Seeking Jobs Abroad Hits Biotech R&D Pipeline 2026-08-01 19:42:55 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 5 Biotech and pharma firms face a growing brain drain as three top U.S. cognitive scientists relocate to the U.K. amid NIH and NSF funding upheavals. A survey shows 75% of scientists are considering leaving, threatening the talent pipeline for drug discovery and clinical research. Full story: https://getbiobrief.com/story/brain-drain-biotech-scientists-uk-trump ### Girl's Death in $860K Gene-Editing Trial Prompts Investigation into Chinese Biotech Ethics 2026-08-01 15:53:36 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2 A young girl's death in an undisclosed gene-editing trial, funded by $860,000 from her parents, has triggered an investigation at Shanghai Jiaotong University. The case exposes critical ethics gaps in China's surging biopharma sector and raises alarms for investors, partners, and regulators worldwide. Full story: https://getbiobrief.com/story/girl-death-gene-editing-trial-chinese-biotech ### 127-Patient Trial of Casdatifan Shows Durable Responses in Advanced Kidney Cancer 2026-07-28 03:57:34 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2 A phase 1 trial of the oral HIF-2α inhibitor casdatifan in 127 heavily pretreated ccRCC patients demonstrated durable tumor responses and a manageable safety profile. The findings, published in Nature, may guide future biomarker-based treatment strategies, potentially reducing futile therapies and optimizing resource use in oncology care. Full story: https://gethealthbrief.com/story/casdatifan-kidney-cancer-trial-health ### Casdatifan’s Phase 1 Data in 127 Kidney Cancer Patients Fuel HIF-2α Competition 2026-07-28 03:57:26 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 Oral HIF-2α inhibitor casdatifan posted durable responses in the ARC-20 phase 1 trial of 127 heavily pretreated ccRCC patients, published in Nature. The data intensifies competition in the HIF-2α space, where Merck’s belzutifan is already approved, and sets the stage for pivotal trials. Full story: https://getbiobrief.com/story/casdatifan-phase1-hif2a-competition ### Gene-Editing Death Rocks Biotech: Trillion-Virus Trial Under Investigation 2026-07-26 14:14:01 · Sector: bio · Sentiment: Strongly negative · Impact: 9/10 · Sources: 2 The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments. Full story: https://getbiobrief.com/story/gene-editing-death-biotech-investigation-ethics --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.